Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thioguanine SCHEMBL9153888 | 0.82 | PDPK1 (0.33) | PDPK1 | |
| SCHEMBL7019371 | 0.79 | PDPK1 (0.36) | PDPK1PARP1 | |
| SCHEMBL1275415 | 0.79 | KDM4E (0.31) | — | |
| Ammonia Solution, Strong SCHEMBL16871771 | 0.78 | PDPK1 (0.35) | PDPK1PARP1 | |
| SCHEMBL753115 | 0.76 | PDK2 (0.38) | PDPK1PARP1 | |
| SCHEMBL11334542 | 0.76 | LMNA (0.33) | PDPK1PARP1 | |
| SCHEMBL21684954 | 0.76 | CSNK2A1 (0.36) | PDPK1PARP1 | |
| Thioguanine SCHEMBL218891 | 0.76 | PDPK1 (0.37) | PDPK1PARP1 | |
| SCHEMBL16147073 | 0.76 | CSNK2A1 (0.36) | — | |
| SCHEMBL218201 | 0.76 | CSNK2A1 (0.37) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| EP-1491201-B1 | Methods of reducing toxicity of 5-fluorouracil with acylated pyrimidine nucleosides | WELLSTAT THERAPEUTICS CORP (US) | 2006-03-22 | — | — | EP | claimed |
| CN-119968127-A | Animal food compositions with improved palatability and customizable properties and methods of making the same | 玛氏公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20250009849-A1 | TOLERIZATION REDUCES INTOLERANCE TO PEGLOTICASE AND PROLONGS THE URATE LOWERING EFFECT (TRIPLE) | HORIZON THERAPEUTICS USA, INC. (US) | 2025-01-09 | — | — | US | disclosed |
| US-12121566-B2 | Methods for treating gout | HORIZON THERAPEUTICS USA, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| CN-116492347-A | Compound for activating AMPK and application thereof | 华安医学股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2020160322-A1 | TOLERIZATION REDUCES INTOLERANCE TO PEGLOTICASE AND PROLONGS THE URATE LOWERING EFFECT (TRIPLE) | HORIZON PHARMA RHEUMATOLOGY LLC (US) | 2020-08-06 | — | — | WO | disclosed |
| US-20200237879-A1 | TOLERIZATION REDUCES INTOLERANCE TO PEGLOTICASE AND PROLONGS THE URATE LOWERING EFFECT (TRIPLE) | HORIZON THERAPEUTICS USA, INC. | 2020-07-30 | — | — | US | disclosed |
| US-9938279-B2 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2018-04-10 | — | — | US | disclosed |
| WO-2016027106-A1 | CELL ASSAY | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2016-02-25 | — | — | WO | disclosed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | disclosed |
| US-5021574-A | Cardiotonic agents, antiarrhythmia agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-06-04 | — | — | US | disclosed |
| US-4622324-A | CARDIOVASCULAR DISORDERS, HYPOTENSIVES | DR. WILLMAR SCHWABE GMBH & CO. (DE) | 1986-11-11 | — | — | US | disclosed |
| US-4603219-A | 1,3-dibenzyloxy-2-acetoxymethoxypropane, intermediate for 9-(1,3-dihydroxy-2-propoxymethyl)guanine | SYNTEX (U.S.A.) INC. (US) | 1986-07-29 | — | — | US | disclosed |
| US-4507305-A | 9-(1,3-Dihydroxy-2-propoxymethyl)guanine as antiviral agent | SYNTEX (U.S.A.) INC. (US) | 1985-03-26 | — | — | US | disclosed |
| EP-0044928-B1 | 1,4;3,6-DIANHYDRO-HEXITE-NITRATE SUBSTITUTED BY PURINE BASES, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITIONS | Dr. Willmar Schwabe GmbH & Co. (DE) | 1985-03-13 | — | — | EP | disclosed |
| US-4479951-A | CORONARY DIESASE | DR. WILLMAR SCHWABE GMBH & CO. (DE) | 1984-10-30 | — | — | US | disclosed |
| US-4423050-A | 9-(1,3-Dihydroxy-2-propoxymethyl)guanine as antiviral agent | SYNTEX (U.S.A.) INC. (US) | 1983-12-27 | — | — | US | disclosed |
| US-4355032-A | 9-(1,3-Dihydroxy-2-propoxymethyl)guanine as antiviral agent | SYNTEX (U.S.A.) INC. (US) | 1982-10-19 | — | — | US | disclosed |
| EP-0044928-A1 | 1,4;3,6-Dianhydro-hexite-nitrate substituted by purine bases, process for their preparation and their pharmaceutical compositions | Dr. Willmar Schwabe GmbH & Co. (DE) | 1982-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | PDPK1 281/4885PARP1 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.